PREPARATION, CHARACTERIZATION, AND EVALUATION OF ANTI-INFLAMMATORY ACTIVITY OF ETORICOXIB LOADED SOLUPLUSÂ® NANOCOMPOSITES
Objective: The objective of this study was to prepare and characterize etoricoxib (ECB) loaded SoluplusÂ® nanocomposites to improve its physicochemical properties. The effect of polymer and surfactant concentration on particle size, in vitro percentage dissolution efficiency and the anti-inflammatory activity of nanocomposites were also investigated.
Methods: The nanocomposites were prepared by using a freeze-drying technique. The analytical evidence for the formulation of lyophilized nanocomposites in solid state were generated and confirmed by differential scanning calorimetry (DSC), fourier transformation infrared spectroscopy (FTIR), x-ray powder diffractometry (XPRD) and scanning electron microscopy (SEM). The in vitro drug release profile of nanocomposites was compared with pure ECB powder.
Results: The nanocomposites of ECB were contained in a nano range with particle size and zeta potential of 63.5 nm and 46.5 mv, respectively. The solubility and dissolution of the nanocomposites were significantly (p<0.001) improved as compared to ECB alone, evidenced by decreased log P values (1.90Â±0.002) of the nanocomposites. The characterization studies revealed the formation of amorphous nanocomposites of ECB with existence of physical interactions between drug and polymer. The anti-inflammatory activity of nanocomposites evaluated by carrageenan-induced rat paw edema model demonstrated nonsignificant (p>0.05) increase in anti-inflammatory activity as compared to pure ECB.
Conclusion: From the results, it could be concluded that the formation of ECB nanocomposites with SoluplusÂ® could be an effective and alternative approach to modify the physicochemical properties of ECB.
2. Raja RK, Abbulu K, Sudhakar M, Vishwanadham M, Syama MT. Studies on dissolution enhancement of Lovaststin using soluplus by solid dispersion technique. Int J Pharm Pharm Sci 2012;4:124-8.
3. Kasar PM, Kale KS, Phadtare DP. Nanoplex: a review of nanotechnology approach for solubility and dissolution rate enhancement. Int J Curr Pharm Res 2018;10:6-10.
4. Amidon GL, Lennernas H, Shaha VP, Crison JR. A theoretical basis for biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability. Pharm Res 1995;12:413-20.
5. Patel RN, Bahareh M, Patel S. Modification of physical and chemical properties of BCS II drug. Int J Pharm Pharm Sci 2012;4:290-302.
6. Muralidhar SM, Rao GD, Murthy MK, Kumar KK, Teja KK, Nawaj S, et al. Enhancement of dissolution rate of etoricoxib through solid dispersion technique. J Appl Pharm Sci 2011;1:129-32.
7. Cochrane DJ, Jarvis B, Keating GM. Etoricoxib. Drugs 2002;62:2637-51.
8. Schott H, Kwan LC, Feldman S. The role of surfactant in the release of very slightly soluble drugs from tablets. J Pharm Sci 1982;71:1038-42.
9. Veiga F, Teixeria Dias JJC, Kedzeierewicz F, Sousa A, Maincent P. Inclusion complexation of tolbutamide with Î²-cyclodextrin and hydroxypropyl-Î²-cyclodextrin. Int J Pharm 1996;129:63-71.
10. Longxiao L, Suyan Z. Preparation and characterization of inclusion complexes of prazosin hydrochloride with Î²-cyclodextrin and hydroxypropyl-Î²-cyclodextrin. J Pharm Biomed Anal 2006;28:122-7.
11. Henck JO, Griesser UJ, Burger A. Polymorphie von arzneistoffen eine wirtschaftliche herausforderung. Pharm India 1997;59:165-9.
12. Hancock BC, Zografi G. Characteristics and significance of the amorphous state in pharmaceutical systems. J Pharm Sci 1997;86:1-12.
13. Chiou WL, Riegelman S. Pharmaceutical applications of solid dispersion systems. J Pharm Sci 1971;60:1281-302.
14. Serajuddin ATM. Solid dispersion of poorly water-soluble drugs: Early promises, subsequent problems, and recent breakthroughs. J Pharm Sci 1999;88:1058-66.
15. Patnaik S, Aditha SK, Rattan T, Kamisetti V. Aceclofenac-soluplusÂ®Nanocomposites for increased bioavailability. SNL 2015;5:13-20.
16. BASF. Technical Information soluplus, BASF. Pharm Ingredients and Services; 2010. p. 1-8.
17. Agrawal NGB, Porras AG. Dose proportionality of oral etoricoxib, a highly selective cyclooxygenase-2 inhibitor, in healthy volunteers. J Clin Pharmacol 2001;41:1106-10.
18. Rodrigues AD, Halpin RA, Geer LA. Absorption, metabolism, and excretion of etoricoxib, a potent and selective cyclooxygenase-2 inhibitor, in healthy male volunteers. Drug Metab Dispos 2003;31:224-32.
19. Suhagia BN, Patel HM, Shah SA, Rathod I, Parmar VK. Preparation and characterization of etoricoxib-polyethylene glycol 4000 plus polyvinylpyrrolidone k30 solid dispersions. Acta Pharm 2006;56:285-98.
20. Chauhan B, Shimpi S, Paradkar A. Preparation and characterization of etoricoxib solid dispersions using lipid carriers by spray drying technique. AAPS Pharm Sci Tech 2005;6:E405-12.
21. Karekar P, Vyas V, Shah M, Sancheti P, Pore YV. Physicochemical investigation of the solid dispersion systems of etoricoxib with poloxamer 188. Pharm Dev Tech 2009;14:373-9.
22. Shimpi SL, Chauhan B, Mahadik KR, Paradkar A. Stabilization and improved in vivo performance of amorphous etoricoxib using gelucire 50/13. Pharm Res 2005;22:1727-34.
23. Shimpi SL, Mahadik KR, Paradkar AR. Study on the mechanism for amorphous drug stabilization using gelucire 50/13. Chem Pharm Bull 2009;57:937-42.
24. Shimpi S, Mahadik K, Takada K, Paradkar K. Application of polyglycolized glycerides in the protection of an amorphous form of etoricoxib during compression. Chem Pharm Bull 2007;55:1448-51.
25. Shah M, Karekar P, Sancheti P, Vyas V, Pore Y. Effect of PVP K30 and/or L-arginine on stability constant of etoricoxib-HP-ï¢-CD inclusion complex: preparation and characterization of etoricoxib-HP-ï¢-CD binary system. Drug Dev Ind Pharm 2009;35:118-29.
26. Patel HM, Suhagia BN, Shah SA, Rathod I, Parmar VK. Preparation and characterization of etoricoxib-Î²-cyclodextrin complexes prepared by the kneading method. Acta Pharm 2007;57:351-9.
27. Dash R, Acharya AK, Swain S, Barg M, Choudhary HK, Meher K. Formulation and evaluation of spherical crystal of etoricoxib. Int J Pharm Biol Arch 2011;2:1123-9.
28. Higuchi T, Connors K. Phase-solubility techniques. Adv Anal Chem Instr 1965;4:117-2.
29. Desai PS, Pore YV. Physicochemical characterization of spray dried cefixime polymeric nanoparticles using a factorial design approach. J Appl Pharm Sci 2016;6:124-32.
30. Khade S, Pore YV. Formulation and evaluation of neusilnÂ® US2 adsorbed amorphous solid self-micro emulsifying delivery system of atorvastatin calcium. Asian J Pharm Clin Res 2016;9:1-8.
31. Jadhav P, Pore YV. Physicochemical, thermodynamic and analytical studies on binary and ternary inclusion complexes of bosentan with hydroxypropyl-Î²-cyclodextrin. Bull Fac Pharm (Cairo Univ) 2016;55:147-54.
32. Naidu G, Madhavi E, Konda VGR, Ramana V. Comparative study of the anti-inflammatory activity of newer macrolides with etoricoxib. J Evol Med Dent Sci 2014;3:2413-9.
33. Ferrero Milianni L, Nielsen OH, Andersen PS. Chronic inflammation: the importance of NOD2 and NALP3 in interleukinâ€“l beta generation. Clin Exp Immunol 2007;147:227-35.
34. Mishara D, Ghosh G, Kumar P, Panda P. Anti-inflammatory and antipyretic activity of selective COX-2 inhibitor with conventional NSAIDS. Int J Pharm Sci Res 2010;1:103-9.
35. Jafar M, Mhg D, Shareef A. Enhancement of dissolution and anti-inflammatory effect of meloxicam using solid dispersion. Int J Appl Pharm 2010;2:22-7.
36. Niazi J, Gupta V, Chakarborty P, Kumar P. Anti-inflammatory and antipyretic activity of aleuritis moluccana leaves. Asian J Pharm Clin Res 2010;3:35-6.
37. Khan KA. The concept of dissolution efficiency. J Pharm Pharmacol 1975;27:48-9.
38. Mooter G, Augustijins, Blaton N, Kinget R. Physico-chemical characterization of solid dispersions of temazepam with polyethylene glycol 6000 and PVP K30. Int J Pharm 1998;164:67-80.
39. Ruan LP, Yu BY, Fu GM, Zhu D. Improving the solubility of ampelopsin by solid dispersions and inclusion complexes. J Pharm Biomed Anal 2005;38:457-64.
40. Bhosale P, Pore YV, Sayyad F. Preparation of amorphous carvedilol polymeric microparticles for improvement of physicochemical properties. J Pharm Investig 2012;42:335-44.